Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

Market Cap	65.99B
Revenue (ttm)	4.25B
Net Income (ttm)	672.56M
Shares Out	1.11B
EPS (ttm)	0.60
PE Ratio	98.61
Forward PE	98.32
Dividend	0.50 (0.85%)
Ex-Dividend Date	May 14, 2025

Volume	3,382,759
Average Volume	4,358,615
Open	61.88
Previous Close	59.08
Day's Range	58.12 - 61.88
52-Week Range	27.66 - 65.63
Beta	0.64
RSI	47.12
Earnings Date	Mar 27, 2026

About SHE:002294

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in ph...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 3,596
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002294

Financial Performance

In 2024, SHE:002294's revenue was 4.01 billion, an increase of 19.22% compared to the previous year's 3.37 billion. Earnings were 601.57 million, an increase of 3.71%.